| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1998;66:482-486
© 1998 The Society of Thoracic Surgeons
a Department of Cardiothoracic Surgery, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Accepted for publication March 27, 1998.
Address reprint requests to Dr Kjaergard, Department of Cardiothoracic Surgery, Gentofte Hospital, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark
Background. The Vivostat System is a medical device for the preparation of an autologous fibrin sealant from 120 mL of the patient’s blood in the operating room. The system is fully automated and microprocessor controlled and is made up of three components: an automated processor unit, an automated applicator unit, and a disposable, single-patient–use unit, which includes a preparation set and a Spraypen applicator. The biochemical process is initiated by batroxobin, which acts upon the fibrinogen in the patient’s plasma. The completion of the process depends entirely on endogenous thrombin in producing the sealant.
Methods. Twenty-four volunteer patients undergoing elective primary coronary artery bypass grafting were randomized to either conventional hemostasis (control group) or the use of Vivostat fibrin sealant as an adjunct to conventional hemostasis. The patients were followed up at 1 month and 1 year.
Results. The preparation process was completed in 30 minutes. No safety issues associated with the use of the sealant were identified. From 120 mL of the patient’s blood the yield of fibrin sealant was 4.5 mL (range, 3.9 to 4.8 mL). There was a favorable trend toward lower amounts of chest tube drainage in the Vivostat group. In the Vivostat group, 1 of 11 patients (9%) required a perioperative transfusion and in the control group 3 of 12 patients (25%) required a perioperative transfusion.
Conclusions. It is possible to prepare autologous fibrin sealant with the Vivostat system in 30 minutes. No exogenous thrombin is required. The sealant has no known adverse effects and may prove to be a useful adjunct to hemostasis in cardiothoracic surgery.
This article has been cited by other articles:
|
|
 |
|
  Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 697 - 703.e3.
|
|
|
|
 |
|
 A. Belboul, L. Dernevik, O. Aljassim, B. Skrbic, G. Radberg, and D. Roberts The effect of autologous fibrin sealant (Vivostat(R)) on morbidity after pulmonary lobectomy: a prospective randomised, blinded study Eur. J. Cardiothorac. Surg., December 1, 2004; 26(6): 1187 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. JONES, S. BURNETT, A. SOUTHGATE, P. SIBBONS, A. O. GROBBELAAR, and C. J. GREEN The Role of Human-Derived Fibrin Sealant in the Reduction of Postoperative Flexor Tendon Adhesion Formation in Rabbits J Hand Surg Eur Vol., June 1, 2002; 27(3): 278 - 282. [Abstract] [PDF]
|
|
|
|
 |
|
 H. K. Kjaergard and H. R. Trumbull Bleeding from the sternal marrow can be stopped using vivostat patient-derived fibrin sealant Ann. Thorac. Surg., April 1, 2000; 69(4): 1173 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Kjaergard, J. H. Pedersen, M. Krasnik, U. S. Weis-Fogh, H. Fleron, and H. E. Griffin Prevention of Air Leakage by Spraying Vivostat Fibrin Sealant After Lung Resection in Pigs Chest, April 1, 2000; 117(4): 1124 - 1127. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
